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Review Article
Chronic Low Dosing of Phosphodiesterase Type 5 Inhibitor for 
Erectile Dysfunction
Hyun Hwan Sung, Sung Won Lee
Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
Oral phosphodiesterase type 5 (PDE5) inhibitors have provided non-invasive, effective, 
and well-tolerated treatments for patients with erectile dysfunction (ED). However, 
many patients with ED are unresponsive to ‘on-demand’ PDE5 inhibitors. In addition, 
the lack of spontaneity and naturalness of the on-demand regimen could be a reason 
for decreased compliance with PDE5 inhibitors. Recently, tadalafil and udenafil were 
approved for low-dose daily administration for the treatment of ED. Since the in-
troduction of the concept of daily administration of PDE5 inhibitors, several reports 
have supported the potential benefits of this therapy for disease modification, improve-
ment of the treatment response in difficult-to-treat populations, spontaneity, and safe-
ty, although further research is needed to better address these hypotheses. In this ar-
ticle, we reviewed the daily administration of PDE5 inhibitors in terms of pharmacoki-
netics, safety, efficacy, and distinct features. 
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INTRODUCTION
Erectile dysfunction (ED) is a chronic condition defined as 
the consistent inability to maintain a sufficient erection for 
satisfactory sexual function. ED is a common disease that 
affects 10 to 30 million men in the United States [1]. The 
disease may be associated with underlying cardiovascular, 
neurological, psychological, and endocrine disorders. At 
present, oral phosphodiesterase type 5 (PDE5) inhibitors 
are the first-line therapy for ED patients, providing non-
invasive, effective, and well-tolerated treatments for ED 
[2,3]. Nevertheless, 30 to 40% of patients fail to respond or 
are not satisfied with on-demand treatment even after cor-
rection of the reversible cause of ED [4]. In addition, the suc-
cess rate is often lower in subpopulations identified as be-
ing more difficult to treat, including those with diabetes 
mellitus (DM), patients with severe vasculogenic ED, and 
post-radical prostatectomy (RP) patients [5,6]. The lack of 
spontaneity and naturalness of the on-demand regimen 
could be reasons for decreased compliance with PDE5 in-
hibitors [7]. Intermittent administration might not be the 
optimal treatment for all men and their partners owing to 
individual patterns of sexual activity [8].
The concept of daily administration of PDE5 inhibitors 
was introduced in an effort to provide another treatment 
option that is closer to a natural sexual life [9-12]. Daily ta-
dalafil provides an alternative to on-demand dosing for 
couples who prefer spontaneous rather than scheduled 
sexual activity or who have frequent sexual activity. Daily 
dosing overcomes the requirement for dosing and sexual 
activity to be temporally linked [2]. In addition, an accumu-
lating body of data supports that daily PDE5 inhibitors 
could provide potential benefits of improved treatment re-
sponse in difficult-to-treat populations, disease mod-
ification, efficacy, and safety for ED of various etiologies 
[13-15].
Tadalafil was first approved for low-dose daily admin-
istration at a dose of 2.5 mg or 5 mg [2]. The pharmacoki-
netic characteristics of tadalafil, with its 17.5-hour 
half-life, make it suitable for daily dosing and achieving a 
steady-state serum concentration [16]. Recently, udenafil 
was also approved for low-dose daily administration at a 
dose of 50 mg [17]. The aim of this article was to provide 
clinically relevant information on daily PDE5 inhibitors by Korean J Urol 2012;53:377-385
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reviewing their pharmacokinetics, safety, and efficacy.
RATIONALE FOR USING CHRONIC PDE5 
INHIBITORS: PHARMACOKINETICS
Tadalafil is a selective and reversible inhibitor of PDE5 
[18]. Tadalafil clearance is predominantly by the hepatic 
metabolism via CYP3A to a catechol that undergoes meth-
ylation and is extensively conjugated to form the major cir-
culating metabolite, a methylcatechol glucuronide. (A mi-
nor amount of the unconjugated metabolite is also detected 
in plasma.) Tadalafil is eliminated primarily as a metabo-
lite in feces (61%) and urine (36%) [19]. A significant erecto-
genic response has been demonstrated within 30 minutes 
after a single 20-mg tadalafil dose [20] with a duration of 
up to 36 hours [21]. In particular, the 17.5-hour half-life of 
tadalafil, which is longer than the half-life of other cur-
rently available PDE5 inhibitors, makes it well suited for 
potential use as daily ED therapy [22]. This longer half-life 
provides a steady-state serum drug concentration with 
low-dose, once-daily administration. 
Although a direct correlation of plasma concentration 
with efficacy has not been established, a total tadalafil 
plasma concentration of 55 ng/ml, which approximates 
90% enzyme inhibition in vitro [16], constituted a reason-
able pharmacodynamic target for clinical development 
with the aim of maintaining these concentrations through-
out the dosing interval. The support for this target is based 
on the 90% level of PDE5 inhibition that results in corpus 
cavernosal relaxation exhibited by sildenafil [23]. Based on 
this level, a predicted tadalafil plasma concentration of 55 
ng/mL provided the pharmacologic rationale for the devel-
opment of a once-daily, 5-mg dose as potentially efficacious 
throughout a 24-hour dosing interval in vitro [16]. 
Examination of tadalafil concentration-time profiles 
suggested that steady state was essentially attained by day 
5 with a plasma concentration 1.6 times that with a single 
dose [22]. Simulations of various dosing intervals illus-
trated the similarity and differences between on-demand 
and daily dosing. In the simulated steady-state, 5 mg of ta-
dalafil taken once daily provided plasma concentrations 
that were similar to those observed 24 hours after 20 mg 
of tadalafil taken either two or three times a week. 
Predicted tadalafil plasma concentrations following the 
daily 5-mg dose were less than those of the twice-weekly 
dose and were equivalent to the thrice-weekly dose [16]. 
When compared with measured tadalafil plasma con-
centrations following single-dose administration of tada-
lafil 20 mg, pharmacokinetic simulations indicated that 5 
mg of daily tadalafil resulted in plasma concentrations less 
than half of the 20-mg on-demand dose during the first day. 
This was approximately equivalent to the second day, but 
higher for the remainder of the week following 5 mg of daily 
tadalafil [16]. The simulated cumulative weekly exposure 
following 5 mg of daily tadalafil was approximately 69% 
higher than after a single 20-mg dose of tadalafil each week. 
This simulated result suggested that for a man anticipat-
ing a single dose of 20 mg of tadalafil per week as part of 
his regular sexual activity, a single daily dose of 5 mg of ta-
dalafil would represent a greater weekly exposure to tada-
lafil [16]. 
Forgue et al. [22] demonstrated the pharmacokinetics of 
tadalafil in healthy subjects for peak plasma concentration 
at steady state (Cmax, ss) and area under the concen-
tration-time curve at steady state (AUCss). The results in-
dicated that the Cmax, ss for 5 mg of daily tadalafil was 26% 
lower than that for tadalafil 10 mg and 63% lower than that 
for 20 mg every 2.65 days. In contrast, the AUCss was ap-
proximately 33% higher than the exposure following 10 mg 
of tadalafil every 2.65 days and 33% lower than the ex-
posure following 20 mg of tadalafil every 2.65 days. 
Therefore, for men who anticipate at least twice-weekly 
use of tadalafil 20-mg therapy, a decrease in plasma con-
centrations with a single daily 5-mg tadalafil dose might 
be advantageous from a tolerability perspective, resulting 
in less overall tadalafil exposure [16,22].
EFFICACY AND RELIABILITY OF CHRONIC PDE5 
INHIBITOR USE
Several randomized, double-blinded, prospective, con-
trolled studies have investigated the improvement in out-
comes of chronic PDE5 inhibitor use in ED patients. A sum-
mary is in Table 1. 
In 2004, McMahon [9] published one of the first reports 
of daily tadalafil in patients with ED. In this open-label, 
flexible-dose (10 or 20 mg) evaluation, 112 men with ED 
who failed to respond to 20 mg of tadalafil on at least six 
occasions and had a sexual encounter profile diary question 
3 (SEP3, successful completion of intercourse) affirmative 
response rate of less than 30% were enrolled. A substantial 
improvement was seen in mean International Index of 
Erectile Function-Erectile Function (IIEF-EF) domain 
scores from 10.3 at baseline to 14.9 after the 4-week on-de-
mand treatment and to 23.1 after 12 weeks of daily dose 
therapy. Favorable responses to SEP3 were 14% at base-
line and increased to 21% after on-demand therapy and 
were 58% for daily therapy with 10 mg and 52% for daily 
therapy with 20 mg. IIEF-EF domain scores normalized to 
41% and 32% of men treated with daily dose therapy com-
pared with none in the on-demand arm. A follow-up, 
randomized, open-label crossover trial compared 12 weeks 
of tadalafil (10 mg daily vs. 20 mg on-demand) in 145 men 
with ED [10]. The baseline IIEF-EF score was 14.6 and in-
creased to 23.3 in the on-demand arm and 26.4 in the daily 
dose arm. Positive responses to SEP3 were 30% at baseline 
and increased to 67% for on-demand therapy and 80% for 
the daily therapy arm. The daily dose was preferred by 72% 
of the patients compared with 28% preferring on-demand 
treatment.
Porst et al. [11] evaluated the efficacy and safety of a sin-
gle daily dose of 5 mg or 10 mg of tadalafil in a multicenter, 
randomized, double-blinded, placebo-controlled study of 
293 men for 12 to 15 weeks. Both the 5-mg and 10-mg doses Korean J Urol 2012;53:377-385
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TABLE 1. Efficacy of daily phosphodiesterase type 5 inhibitors
Study Treatment Patient Outcome Result
McMahon [9,10]
Porst et al. [11,24]
Rajfer et al. [12]
Kang et al. [26]
Zhao et al. [17]
Tadalafil 10 mg or 20 mg 
daily, noncomparative 
study for 12 weeks
Tadalafil 10 mg daily vs. 20 
mg on-demand, 
cross-over study
Tadalafil 5 mg or 10 mg 
daily vs. placebo for 12 
weeks
Tadalafil 5 mg or 10 mg 
daily for 12 weeks, and 
tadalafil 2.5 mg or 5 mg 
daily vs. placebo for 24 
weeks
Tadalafil 2.5 mg or 5 mg 
daily vs.placebo for 24 
weeks
Tadalafil 5 mg daily, 
noncomparative study 
for 8 weeks
Udenafil 25 mg, 50 mg or 75 
mg daily vs. placebo for 12 
weeks
Men with ED for at least 
6 months, who failed to 
respond to on-demand 20 
mg tadalafil
Men with ED for at least 
6 months
Men with ED for at least 
3 months
Men with ED for at least 
3 months
Men with ED for at least 
3 months
Men with IIEF-5＜18
Men with ED for 6 months
IIEF-EF domain, SEP2, 
SEP, GAQ
IIEF-EF domain, SEP2, 
SEP3, GAQ, TPQ
IIEF-EF domain, SEP2, 
SEP3 
IIEF-EF, IS and OS 
domain, GAQ 
IIEF, SEP, GAQ and 
PAIRS
IIEF-5, GAQ 
IIEF-EF domain, SEP2, 
SEP3, GAQ 
Tadalafil daily 10 mg or 20 
mg was effective for 
previous on-demand 
tadalafil  nonresponders
Daily tadalafil was 
associated with superior 
outcome regarding 
erectile function and 
preference compared 
with on-demand regimen
Tadalafil significantly 
improved EF relative to 
placebo regardless of 
baseline ED severity
Mean IIEF domain scores 
improved in both arms
Tadalafil significantly 
improved erectile 
function compared with 
placebo 
Tadalafil significantly 
improved EF
50 mg or 75 mgudenafil 
significantly improved 
IIEF-EF, SEP2, SEP3 
and GAQ score compared 
with placebo
ED, erectile dysfunction; IIEF-EF, International Index of Erectile Function-Erectile Function; SEP, sexual encounter profile; GAQ, 
global assessment question; TPQ, treatment preference question; IS, intercourse satisfaction; OS, overall satisfaction; PAIRS, 
Psychological and Interpersonal Relationship Scales.
significantly improved EF with a mean change in IIEF-EF 
domain score of 9.7, 9.4, and 0.9 for the 5 mg, 10 mg, and 
placebo groups, respectively. The authors also reported in 
1- to 2-year open-label extension studies that 5 mg of tada-
lafil once daily for up to 2 years is well tolerated and effec-
tive in men with ED [24]. Mean IIEF domain scores im-
proved from baseline to the conclusions of the 1- and 2-year 
open-label extensions. EF improved by 10.4 and 10.8 at 1 
and 2 years, intercourse satisfaction (IS) improved by 4.0 
and 3.7, and overall satisfaction (OS) improved to 3.0 and 
3.2. At the conclusion of the 2-year open-label extension, 
positive responses were reported for 95.7% of the global as-
sessment question 1 (GAQ, improved erection) and 92.1% 
of GAQ2 (improved ability to engage in sexual activity). 
Interestingly, the mean IIEF-EF score declined to near 
baseline levels after discontinuation of tadalafil at the end 
of the 1-year open-label period.
Rajfer et al. [12] reported on 2.5 mg or 5 mg of tadalafil 
daily vs. placebo in men with ED over 24 weeks. Tadalafil 
was superior to placebo at both dosages for all primary effi-
cacy endpoints. The mean IIEF-EF score increased by 6.1 
in the 2.5-mg tadalafil arm and by 7.0 in the 5-mg arm com-
pared with an increase of 1.2 points for the placebo. 
Tadalafil also produced significant changes in other IIEF 
domains including IS, sexual confidence, and OS with sex-
ual life. 
Shabsigh et al. [25] examined reliability, defined as suc-
cessful attempts/total attempts following initial successful 
intercourse, of tadalafil once daily by using data pooled 
from two previous studies [11,12]. The first-attempt suc-
cess rate (SEP3) was significantly higher among men tak-
ing 2.5 mg (45.7%) and 5 mg (55.2%) tadalafil compared 
with placebo (28.5%). Furthermore, following initial suc-
cess, men taking 5 mg tadalafil had a significantly greater 
proportion of SEP3 on subsequent attempts (85.9%) com-
pared with men taking placebo (70.2%). Overall, men with 
ED taking tadalafil once daily experienced a high rate of 
reliability of efficacy. 
In Korea, Kang et al. [26] evaluated the efficacy of 5 mg 
tadalafil daily in Korean men with ED. A total of 162 men Korean J Urol 2012;53:377-385
380 Sung and Lee
were administered a daily dose of 5 mg of tadalafil and 127 
men completed the 8-week clinical trial. IIEF-5 values sig-
nificantly increased from 11.3 at baseline to 16.9 at 8 
weeks. They concluded that 5 mg of tadalafil daily might 
be effective in improving EF without significant adverse 
events. 
Tadalafil 5 mg was the first ED treatment to be approved 
for daily administration [2]. Few studies have investigated 
daily administration of other PDE5 inhibitors, possibly be-
cause of pharmacokinetic properties such as a relatively 
short half-life, which is 3.8 and 3.9 hours for sildenafil and 
vardenafil, respectively. Of these, sildenafil leads to a sig-
nificant improvement in the recovery of EF after RP [27] 
and improved endothelial function and reduces markers of 
vascular inflammation in men with type 2 diabetes [28]. 
Zumbe et al. [29] demonstrated that once-daily vardenafil 
did not produce greater sustained effects on EF than did 
on-demand vardenafil in men with mild-to-moderate ED, 
suggesting that daily dosing of PDE5 inhibitors does not 
produce sustained clinical benefits beyond cessation of 
treatment above those observed with on-demand admini-
stration. In contrast, udenafil has a relatively long half-life 
(7.3 to 12.1 hours) compared with sildenafil and vardenafil, 
although this is shorter than tadalafil [30]. A recent study 
of daily udenafil showed the possibility of daily admin-
istration of this PDE5 inhibitor [17]. In this study, udenafil 
significantly improved EF among ED patients when ad-
ministered at 50 mg or 75 mg once daily for 12 weeks. The 
authors concluded that daily udenafil (50 mg) could be an-
other treatment option for ED. In Korea, udenafil 50 mg 
is also approved for daily administration.
SAFETY OF CHRONIC PDE5 INHIBITOR 
TREATMENT
The safety of daily PDE5 inhibitor treatment is established 
by many studies that indicate minimal, well-tolerated ad-
verse events that are not significantly different from those 
reported for on-demand regimens (Table 2) [9-12,15,17,24, 
26,31]. Adverse events are reported as mild or moderate in 
severity. The most common adverse events reported are 
headache, dyspepsia, facial flushing, back pain, nasal con-
gestion, and nasopharyngitis [9-12,15,24,26,31-33]. In ad-
dition, the rate of discontinuation caused by adverse events 
is similar to the rate observed with on-demand dosing [24]. 
The range of reported discontinuation rates from adverse 
events of daily administration are 1 to 6%. The most com-
mon adverse events causing discontinuation are dyspep-
sia, headache, back pain, and flu-like symptoms. 
Although PDE5 inhibitors have favorable cardiovas-
cular effects, data on adverse events from daily regimens 
are lacking [12,24]. Kloner et al. [34] conducted a retrospec-
tive analysis of serious cardiovascular adverse events in 36 
clinical trials of tadalafil. A serious cardiovascular adverse 
event was defined as myocardial infarction, cardiovascular 
death, or cerebrovascular death. Tadalafil 2 to 50 mg was 
taken as needed, three times/wk, or once daily. The in-
cidence rates of serious cardiovascular adverse events 
were comparable among men with ED taking tadalafil as 
needed, three times/wk, or once daily, and these rates were 
also comparable with placebo-treated patients. In this clin-
ical trial population of men with ED, tadalafil was not asso-
ciated with an increased risk for serious adverse car-
diovascular events. 
PDE5 inhibitors cross the blood-retina barrier and can 
inhibit retina-specific PDE6, which is structurally similar 
to PDE5 and is involved in regulating the phototrans-
duction cascade. Off-target inhibition of PDE6 is believed 
to be the mechanism for blurred vision, blue-tinged vision, 
and altered perception of light with PDE5 inhibitors, symp-
toms that are typically mild and transient [35,36]. Acute 
administration of sildenafil at high doses produces only 
very mild electroretinographic (ERG) changes that are 
reversible. Some visual complications of long-term use 
have been suggested, including nonarteritic anterior is-
chemic optic neuropathy, central serous chorioretinop-
athy, and vascular events [37-39]. Only a few studies have 
investigated the retinal effects of chronic PDE5 inhibitors. 
Cordell et al. [40] assessed ERG changes and changes in 
retinal function during 6 months of daily use of 5 mg of tada-
lafil, 20 mg of sildenafil, or placebo. No significant differ-
ences were found between the treatment and placebo 
groups for the outcome of ERG or other parameters such 
as visual acuity, color discrimination, visual-field testing, 
and intraocular pressure. The visual safety of daily tadala-
fil and sildenafil should be assessed over a prolonged 
period. 
Although only two randomized, double-blind, place-
bo-controlled studies have evaluated semen character-
istics after daily PDE5 inhibitors, the results of these stud-
ies were consistent. In a noninferiority trial, Hellstrom et 
al. [41] concluded that there were no deleterious effects of 
long-term (40 weeks), daily treatment with 20 mg of tadala-
fil on spermatogenesis or hormones related to testicular 
function in men older than 45 years. Daily tadalafil was not 
inferior to placebo for sperm concentration and count, mo-
tile sperm, or normal sperm morphology, with a non-
inferiority margin of 20%. Among the reproductive hor-
mones tested, only total testosterone was significantly dif-
ferent (higher than placebo) between groups at the 
end-point. Daily vardenafil also has no detrimental effects 
on semen characteristics or reproductive hormones in men 
with normal baseline levels [42]. The percentage of pa-
tients with a 50% or greater decrease in sperm concen-
tration (baseline to 6 months last observation carried for-
ward) was 0.07%. Vardenafil also had no clinically sig-
nificant effects on any other semen parameters, or on levels 
of reproductive hormones, compared with placebo.
ADVANTAGES OF CHRONIC PDE5 INHIBITOR 
USE IN MEN WITH ED
Accumulating data demonstrate several benefits of daily 
PDE5 inhibitors as well as efficacy and safety. These ad-Korean J Urol 2012;53:377-385
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TABLE 2. Safety of daily phosphodiesterase type 5 inhibitors
Study Treatment Common adverse event Discontinuation due to adverse event
Rajfer et al. [12]
Kang et al. [26]
Ricardi et al. [15]
Porst et al. [68]
Zhao et al. [17]
Egerdie et al. [31]
Oelke et al. [69]
Tadalafil 2.5 mg or 5 mg for 24 weeks
Tadalafil 5 mg daily for 8 weeks
Tadalafil 5 mg for 12 weeks after 
radiotherapy
Tadalafil 5 mg for 12 weeks
Udenafil 50 mg or 75 mg daily for 12 weeks
Tadalafil 2.5 mg or 5 mg daily for 12 weeks
Tadalafil 5 mg in patients with BPH for 12 
weeks
2.5 mg
Nasopharyngitis (6.3%)
Back pain (5.2%)
Dyspepsia (4.2%)
Myalgia (4.2%)
5 mg
Nasopharyngitis (6.3%)
Nasal congestion (4.1%)
Back pain (2.1%)
Hot flushing (2.4%)
Headache (1.6%)
Dizziness (1.6%)
Headache (16%)
Dyspepsia (12%)
Myalgia (8%)
Headache (3.7%)
Back pain (3.1%)
50 mg
Hot flushing (8.3%)
Head ache (1.7%)
Nausea (1.7%)
Urticaria (1.7%)
75 mg
Hot flushing (6.8%)
Head ache (3.4%)
Nasal congestion (1.7%)
2.5 mg
Nasopharyngitis (3.0%)
Headache (2.5%)
Back pain (0.5%)
5 mg
Headache (5.8%)
Back pain (2.9%)
Nasopharyngitis (2.4%)
Headache (2.9%)
Nasopharyngitis (2.9%)
Back pain (2.3%)
Dizziness (2.3%)
Dyspepsia (2.3%)
2.5 mg: 2.1%
Acute myocardiac infarction (1.0%)
Chest pain (1.0%)
5 mg: 3.1%
Back pain (1.0%)
Pancreatitis (1.0%)
Traffic accident (1.0%)
None
4.0% 
Headahce (4.0%)
1.9%
Upper abdominal pain (0.6%)
Headache (0.6%)
Acute myocardiac infarction (0.6%)
Not commented
2.5 mg: 1.5%
5 mg: 2.9%
1.2%
BPH, benign prostatic hyperplasia.
vantages include sexual quality of life, efficacy in diffi-
cult-to-treat populations, onset of efficacy, and durability 
and improvement of benign prostatic hyperplasia (BPH) 
symptoms. 
1. Sexual quality of life 
Women with partners currently treated with daily PDE5 
inhibitors had an improved sexual quality of life [43-45]. 
Daily 5 mg tadalafil significantly improved EF and sexual 
quality of life for men with ED but also for their female part-
ners [43]. Tadalafil 5 mg taken once daily as an ED treat-
ment improved OS for men and their female partners [44]. 
The analysis demonstrated a high concordance among cou-
ples in their responses to the man’s ED treatment. After 
12 weeks of daily 5-mg tadalafil treatment, the partic-
ipants and their partners were more satisfied [45]. In addi-
tion, significant improvements in sexual relationship, con-
fidence, self-esteem, and overall relationship were corre-
lated with EF improvement.
2. Difficult-to-treat populations
Daily PDE5 inhibitor administration has been evaluated 
in difficult-to-treat populations. Nonresponders to on-de-
mand PDE5 inhibitors range from 30 to 35% [4,46]. Patient 
education, lifestyle modification, correction of modifiable 
risk factors, dose adjustment or change in PDE5 inhibitors, Korean J Urol 2012;53:377-385
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counseling, and progression to second-line or third-line 
treatment are additional salvage methods. Hatzimourati-
dis et al. [2] reported that nonresponders to on-demand 
PDE5 inhibitor use were salvaged following daily admin-
istration of tadalafil (11.1%) and vardenafil (18.2%). 
McMahon [9] also showed the ability of daily tadalafil to 
act as salvage therapy in patients previously unresponsive 
to on-demand 20 mg tadalafil. The diabetic population has 
a high prevalence of ED, and ED develops earlier in this 
population than in men without DM [47]. In addition, ED 
in men with DM can be more severe and is more likely to 
be refractory to treatment [48-50]. In several studies of men 
with diabetes and ED, daily treatment with PDE5 in-
hibitors was efficacious [13] and improved endothelial 
function, which suggests that diabetes-induced impair-
ment of endothelial function might be improved by pro-
longed PDE5 inhibition [28]. 
Loss of sufficient EF is one of the most common complica-
tions following RP. This is mainly due to cavernous nerve 
damage resulting in penile hypoxia, smooth muscle apop-
tosis, fibrosis, and veno-occlusive dysfunction [14]. The 
goal of early penile rehabilitation is to prevent ED after RP 
by countering pathologic changes using PDE5 inhibitors. 
Daily low-dose sildenafil leads to a significant improve-
ment in the recovery of EF after RP [27]. Recent animal 
studies provide further support for daily PDE5 inhibitors 
in this group of patients [51,52]. In a rat model of bilateral 
cavernous nerve crush injury, chronic administration of 
udenafil preserved EF and was beneficial against the path-
ophysiological consequences of cavernous nerve injury 
[52]. ED has been suggested as a late effect of radiation 
therapy (RT) for prostate cancer [53,54]. The underlying 
mechanism is largely unknown, although some clinical and 
animal studies suggest that ED after radiotherapy might 
be caused by radiation damage to the arterial supply of the 
corpora cavernosa [53,55]. Ricardi et al. [15] compared the 
efficacy and safety of on-demand 20 mg tadalafil with daily 
5 mg tadalafil in ED patients following RT for prostate 
cancer. In this study, once-a-day 5-mg dosing showed high-
er compliance and marginally reduced side effects, making 
it an attractive alternative to on-demand therapy for ED 
in post-RT prostate cancer patients.
3. Onset of efficacy
Onset of efficacy is an important factor when evaluating 
PDE5 inhibitors [56]. Several studies have demonstrated 
the rapid onset of efficacy of on-demand PDE5 inhibitors 
in men with ED [20,56,57]. Although onset of efficacy is a 
more important consideration in daily treatment because 
of the relatively low dose that is used, few studies have in-
vestigated this concern. In efficacy and safety trials for dai-
ly tadalafil, an average of 80% of men achieved a successful 
attempt by day 4 with 5 mg of tadalafil, by day 5 with 2.5 
mg of tadalafil, and by day 7 with placebo [11,12]. Seftel et 
al. [58] reported that more men in the tadalafil 5 mg group 
than in the placebo group achieved successful intercourse 
by day 2 (48.6% vs 36.6%), although steady-state tadalafil 
was essentially attained by day 5 [22]. The 2.5-mg tadalafil 
group was not different from the placebo group by day 2, 
but did differ by day 3 (35.5% vs. 27.2%). This prospective 
trial concluded that the onset of efficacy of once-daily 
2.5-mg and 5-mg doses of tadalafil was within a few days 
of initiating therapy.
4. Durability
A sustained erectile effect after cessation of ED treatment 
is a one of the most interesting and important discussion 
points when considering daily PDE5 inhibitors for ED 
treatment. Several previous studies primarily focused on 
improvement of EF with daily PDE5 inhibitors during 
treatment, but less is known about what occurs after treat-
ment cessation. Although PDE5 inhibitors are not consid-
ered a cure for ED [59], several studies of chronic admin-
istration of a PDE5 inhibitor have demonstrated improve-
ment in EF beyond discontinuation of treatment 
[28,60-62]. Porst et al. [63] reported that in men who dem-
onstrated improved EF while taking 5 mg of daily tadalafil 
for 1 year, 46.3% continued to show improvement com-
pared with baseline following a 4-week treatment-free 
period. In this study, more men with diabetes and hyper-
tension had a durable response. This suggests that pa-
tients with endothelial damage are more likely to experi-
ence sustainable benefit from long-term PDE5 inhibitor 
treatment for ED. In contrast, some studies had negative 
findings for durability. Although administration of tadala-
fil decreased the serum endothelial microparticle concen-
tration, which was selected as a marker of endothelial dam-
age, in patients with arterial ED, this positive effect on en-
dothelial dysfunction disappeared 6 months after tadalafil 
discontinuation [64]. Following discontinuation of tadala-
fil after a 1-year open-label extension, the mean IIEF-EF 
score declined markedly to near baseline levels [24]. 
Durability of response should be a focus of future research 
when evaluating daily PDE5 inhibitors. 
5. Effect on BPH symptoms
Tadalafil was recently approved in the United States for 
treatment of the signs and symptoms of BPH and for the 
treatment of coexisting BPH and ED. Several clinical stud-
ies have shown that PDE5 inhibitors can improve BPH-re-
lated lower urinary tract symptoms [31,65-69]. Porst et al. 
[68] assessed the efficacy, onset, and safety of daily 5 mg 
tadalafil on BPH symptoms in a randomized, double-blind, 
placebo-controlled study. This study concluded that 5 mg 
of tadalafil daily for 12 weeks resulted in a clinically mean-
ingful reduction in total International Prostate Symptom 
Score as early as 1 week and achieved significance at 4 
weeks in men with BPH. Egerdie et al. [31] also demon-
strated the efficacy of daily 5 mg tadalafil on both ED and 
BPH in a multinational phase 3 study. Interestingly, 5 mg 
of tadalafil or 0.5 mg of tamsulosin once daily resulted in 
significant and similar improvements in BPH symptoms 
compared with placebo in as little as 1 week and throughout 
the 12-week treatment period. In addition, tadalafil and Korean J Urol 2012;53:377-385
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tamsulosin similarly improved the maximum urinary flow 
rate through 12 weeks [69].
LIMITATIONS OF CHRONIC PDE5 INHIBITOR USE 
IN MEN WITH ED
Several published studies have supported low-dose, chron-
ic PDE5 inhibitors as an efficacious and safe option for 
treating ED. Nevertheless, some limitations exist to ex-
tending their use. The aspect of disease modification and 
durability after cessation of chronic use should be verified 
when evaluating daily PDE5 inhibitors. Furthermore, 
head-to-head trials are needed between on-demand and 
daily PDE5 inhibitors to remedy the lack of comparative 
data. 
Most clinical trials and research on the chronic use of 
PDE5 inhibitors has focused on tadalafil because of its 
pharmacokinetic characteristics. Tadalafil 5 mg is the only 
drug currently approved for daily administration for ED 
treatment, but no other choice has been considered for 
chronic use of a PDE5 inhibitor. One of the most recently 
developed PDE5 inhibitors, udenafil, has a relatively long 
half-life that is more similar to that of tadalafil than to sil-
denafil or vardenafil. Recent data show promising results 
that udenafil could be another option for chronic use in men 
with ED. 
Treatment cost is an important factor for patient com-
pliance in low-income households, despite the fact that the 
treatment is highly effective and improves the partner re-
lationship [70]. In addition, cost is the most common reason 
for rehabilitation neglect in patients who have undergone 
RP [71]. The influence of costs of daily PDE5 inhibitors is 
not yet established in men with ED but could negatively 
influence patient compliance. 
CONCLUSIONS
Clinical trials with low-dose, daily PDE5 inhibitors, espe-
cially tadalafil, confirm the efficacy and safety of such 
treatment. Daily administration of a PDE5 inhibitor pro-
vides a treatment alternative that could be suitable for dif-
ficult-to-treat populations with ED as well as providing 
spontaneity and naturalness that does not require consid-
eration of the timing of sexual activity. This suggests that 
the option of daily administration of PDE5 inhibitors could 
be offered to any ED patients. 
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